Cardiologist and digital health pioneer Eric Topol is calling for a fundamental shift in medicine-from treating disease to preventing it. In a recent interview, Topol outlined how innovations in genomics, AI, and wearable sensors are converging to create a new era of personalized, proactive healthcare.
Topol argues that the biggest opportunity ahead is the prevention of major diseases like cardiovascular disease, cancer, and neurodegenerative conditions. He emphasizes that we now have a powerful toolkit to assess risk: not just standard metrics like cholesterol, but also polygenic risk scores, whole genome sequencing, and advanced imaging to detect arterial inflammation. This data can identify risk decades before a heart attack strikes.
Despite these advances, Topol voiced frustration that genomic information is still not routinely used in cardiology. He cited examples where whole genome sequencing altered clinical management in cancer patients but remains underutilized in heart care. He advocates for integrating polygenic risk scores and pharmacogenomics into everyday practice.
The proliferation of wearable sensors and continuous monitoring devices is another key theme. Topol believes we are moving toward a "hospital-at-home" model, where validated algorithms and multimodal AI can keep patients safe in their own homes, reducing the need for traditional hospitalization.
Topol's concept of "Deep Medicine" envisions AI restoring the patient-doctor relationship by automating administrative tasks like note-taking. He notes that ambient AI can draft clinical notes better and faster than physicians, freeing up time for genuine connection. Patients are also gaining autonomy, using AI to interpret lab results and prepare for visits.
Looking ahead, Topol is excited about the potential of AI-interpreted imaging. He describes how AI can guide untrained individuals to perform complex scans like echocardiograms, matching or exceeding expert cardiologists. Integrating imaging with lab data, genomics, and sensor data could enable true predictive health.
However, Topol cautions against the risks: AI could worsen health inequities if not carefully designed. He stresses the need for rigorous validation research to ensure safety and equity.
Topol’s vision for the next 10-20 years is one where cardiovascular disease becomes "eminently preventable." He points to new drugs that block inflammation as a turning point, alongside lifestyle modifications and environmental remediation.
"We are now empowered," Topol says. "We’re not yet fully using the information that we have, but we will. It is inevitable."